Payer insights for cell and gene therapies
It is essential to address the payer landscape very early in development for a product administered once with a lifelong effect, such as a gene therapy. The one-time, front-loaded costs of these treatments have necessitated new payment models to win payer approval and be affordable. In this short video, Emma Medin, VP, Pricing & Market Access, shares three payer insights to help you price appropriately for your cell or gene therapy. Get more insights from our experts by visiting https://www.parexel.com/neverstop.